SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

被引:204
|
作者
Andreano, Emanuele [1 ]
Piccini, Giulia [2 ]
Licastro, Danilo [3 ]
Casalino, Lorenzo [4 ]
Johnson, Nicole, V [5 ]
Paciello, Ida [1 ]
Dal Monego, Simeone [3 ]
Pantano, Elisa [1 ]
Manganaro, Noemi [1 ]
Manenti, Alessandro [2 ,6 ]
Manna, Rachele [2 ]
Casa, Elisa [2 ,6 ]
Hyseni, Inesa [2 ,6 ]
Benincasa, Linda [6 ]
Montomoli, Emanuele [2 ,6 ,7 ]
Amaro, Rommie E. [4 ]
McLellan, Jason S. [5 ]
Rappuoli, Rino [1 ,8 ]
机构
[1] Fdn Toscana Life Sci, Monoclonal Antibody Discovery Mad Lab, I-53100 Siena, Italy
[2] VisMederi Srl, I-53100 Siena, Italy
[3] ARGO Open Lab Platform Genome Sequencing, I-34149 Trieste, Italy
[4] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[5] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA
[6] VisMederi Res Srl, I-53100 Siena, Italy
[7] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy
[8] Imperial Coll, Fac Med, London SW7 2DD, England
关键词
SARS-CoV-2; COVID-19; emerging variants; immune evasion; antibodyresponse;
D O I
10.1073/pnas.2103154118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To investigate the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for seven passages, but, after 45 d, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed, at day 80, by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom, South Africa, Brazil, and Japan of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Covid-19 convalescent plasma and SARS-CoV-2 viral variants
    Joob, B.
    Wiwanitkit, V.
    [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (03) : 306 - 306
  • [2] Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
    von Rhein, Christine
    Scholz, Tatjana
    Henss, Lisa
    Kronstein-Wiedemann, Romy
    Schwarz, Tatjana
    Rodionov, Roman N.
    Corman, Victor M.
    Tonn, Torsten
    Schnierle, Barbara S.
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2021, 288
  • [3] Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
    Inada, Makoto
    Togano, Tomiteru
    Terada, Mari
    Shiratori, Katsuyuki
    Tsuzuki, Shinya
    Takamatsu, Yuki
    Saito, Sho
    Hangaishi, Akira
    Morioka, Shinichiro
    Kutsuna, Satoshi
    Maeda, Kenji
    Mitsuya, Hiroaki
    Ohmagari, Norio
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (03)
  • [4] Investigation of SARS-CoV-2 RNAemia in the convalescent plasma of COVID-19 patients
    Perumal, N.
    Jain, R. K.
    Chaurasia, D.
    Sharma, U. M.
    Malik, R.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S37 - S37
  • [5] Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
    Takamatsu, Yuki
    Imai, Masaki
    Maeda, Kenji
    Nakajima, Noriko
    Higashi-Kuwata, Nobuyo
    Iwatsuki-Horimoto, Kiyoko
    Ito, Mutsumi
    Kiso, Maki
    Maemura, Tadashi
    Takeda, Yuichiro
    Omata, Kazumi
    Suzuki, Tadaki
    Kawaoka, Yoshihiro
    Mitsuya, Hiroaki
    [J]. JOURNAL OF VIROLOGY, 2022, 96 (04)
  • [6] Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors
    Annen, Kyle
    Morrison, Thomas E.
    DomBourian, Melkon G.
    McCarthy, Mary K.
    Huey, Leah
    Merkel, Patricia A.
    Andersen, Gillian
    Schwartz, Eileen
    Knight, Vijaya
    [J]. TRANSFUSION, 2021, 61 (04) : 1148 - 1159
  • [7] Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant
    Gallian, Pierre
    Amroun, Abdennour
    Laperche, Syria
    Le Cam, Sophie
    Brisbarre, Nadege
    Malard, Lucile
    Nurtop, Elif
    Isnard, Christine
    Richard, Pascale
    Morel, Pascal
    Tiberghien, Pierre
    de Lamballerie, Xavier
    [J]. VOX SANGUINIS, 2022, 117 (07) : 971 - 975
  • [8] Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants
    Di Germanio, Clara
    Simmons, Graham
    Thorbrogger, Chloe
    Martinelli, Rachel
    Stone, Mars
    Gniadek, Thomas
    Busch, Michael P.
    [J]. TRANSFUSION, 2022, 62 (03) : 563 - 569
  • [9] COVID-19 Convalescent Plasma Donor Characteristics and Sars-Cov-2 Antibody Status
    Hayes, Chelsea A.
    Gibb, David R.
    Pepkowitz, Samuel H.
    Halprin, Chelsea E.
    Rojo, Josephine
    Tanaka, Julie
    Klapper, Ellen B.
    [J]. TRANSFUSION, 2020, 60 : 98A - 99A
  • [10] Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2
    Nguyen, Freddy T.
    van den Akker, Tayler
    Lally, Kimberly
    Lam, Hansen
    Lenskaya, Volha
    Liu, Sean T. H.
    Bouvier, Nicole M.
    Aberg, Judith A.
    Rodriguez, Denise
    Krammer, Florian
    Strauss, Donna
    Shaz, Beth H.
    Rudon, Louella
    Galdon, Patricia
    Jhang, Jeffrey S.
    Arinsburg, Suzanne A.
    Baine, Ian
    [J]. TRANSFUSION, 2021, 61 (01) : 78 - 93